ANI PHARMACEUTICALS INC ANIP

Healthcare SIC 2834 - Pharmaceutical Preparations NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing derived Nasdaq

ANI Pharmaceuticals is a diversified bio-pharmaceutical company. The Company's mission is "Serving Patients, Improving Lives" by developing, manufacturing, and commercializing therapeutics through its Rare Disease, Generics, and Brands businesses.

On September 16, 2024, the Company acquired Alimera Sciences, Inc. ("Alimera"). In connection with the acquisition, the Company added two new products, ILUVIEN® ("ILUVIEN") and YUTIQ® ("YUTIQ"). See Note 3 "Business Combination" in the notes to the consolidated financial statements in Part II, Item 8 of this Annual Report on Form 10-K.

During March 2025, the FDA approved an expanded label for ILUVIEN to include an indication for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye ("NIU-PS") in addition to the then-current indication of Diabetic Macular Edema ("DME"). The Company is currently marketing ILUVIEN for both indications in the U.S. ILUVIEN was already approved for both DME and NIU-PS outside the U.S., including in seventeen European countries. During the second quarter of 2025, the Company transitioned promotional efforts in the U.S. from YUTIQ to ILUVIEN with its combined label of DME and NIU-PS.

Last close 72.61 2026-10-23
Market cap $1.54B estimated share count
52-week range 69.58 - 95.57

Valuation FY2025 figures against the last close

P/S1.7x
P/E21.9x
P/FCF9.0x
EV/EBITDA13.0x
Dividend yield0.1%
Diluted EPS3.32

Where the revenue comes from as reported in the latest 10-K

Revenue by geography

  • United States
  • International
Revenue by geography, 2 categories over 1 years. The same figures are in the table below. FY2025 United States, FY2025: 852.4M (96.5%) 96% United States International, FY2025: 30.9M (3.5%) 4%
Region FY2025
United States $852.4M
International $30.9M

As the company reported it, from the “SEGMENT REPORTING - Geographic (Details)” note of its latest 10-K. Every figure here has been checked against the total revenue the same filing reported. Regions are the filer's own and are not mapped onto a standard list — one company's “Americas” and another's “United States” are different areas, and making them look comparable would mean making at least one of them wrong. Slices under 1% are folded into “Other”.

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $883.4M$614.4M$486.8M$316.4M$216.1M$208.5M$206.5M$201.6M$176.8M$128.6M
Cost of revenue —————$87.2M$63.2M$73.0M$79.0M$48.8M
Gross profit —————$121.3M$143.4M$128.6M$97.8M$79.8M
R&D $51.7M$44.6M$34.3M$22.3M$11.4M$16.0M$19.8M$15.4M$9.1M$2.9M
SG&A $317.7M$249.6M$161.7M$124.0M$84.3M$65.0M$55.8M$44.1M$31.6M$27.8M
Total operating expenses $772.3M$613.8M$439.8M$351.7M$255.9M$224.5M$190.2M$166.2M$148.5M$108.5M
Operating income $111.1M$584.0K$47.0M-$35.3M-$39.8M-$16.0M$16.4M$35.4M$28.3M$20.1M
Pre-tax income $95.8M-$22.2M$19.9M-$62.7M-$56.1M-$26.0M$3.2M$20.1M$16.3M$8.7M
Income tax $17.5M$3.7M$1.1M$14.8M$13.5M$3.4M$2.9M$4.6M$17.4M$4.7M
Net income $78.0M-$19.0M$19.0M-$48.0M-$43.0M-$22.5M$6.1M$15.5M-$1.1M$3.9M
EPS, basic 3.50-1.040.86-3.05-3.40-1.880.511.31-0.090.34
EPS, diluted 3.32-1.040.85-3.05-3.40-1.880.501.30-0.090.34
Shares, diluted (wtd. avg.) 21.2M19.3M18.2M16.3M12.6M12.0M12.0M11.8M11.5M11.6M

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $285.6M$144.9M$221.1M$48.2M$100.3M$7.9M$62.3M$43.0M$31.1M$27.4M
Receivables $281.1M$221.7M$162.1M$165.4M$128.5M$95.8M$72.1M$64.8M$58.8M$45.9M
Inventory $143.1M$136.8M$111.2M$105.4M$81.7M$60.8M$48.2M$40.5M$37.7M$26.2M
Total current assets $753.1M$528.5M$519.8M$344.3M$321.8M$170.3M$187.7M$152.9M$131.6M$103.0M
Property, plant and equipment $62.5M$56.9M$44.6M$43.2M$52.7M$41.3M$40.6M$38.1M$20.4M$11.0M
Goodwill $62.5M$60.0M$28.2M$28.2M$27.9M$3.6M$3.6M$3.6M$1.8M$1.8M
Other intangibles $479.5M$541.8M$209.0M$251.6M$294.1M$188.5M$180.4M$201.6M$229.8M$175.8M
Total assets $1.44B$1.28B$904.4M$760.1M$771.6M$461.2M$456.8M$430.6M$412.1M$322.9M
Accounts payable $62.6M$45.7M$36.7M$29.3M$23.0M$11.3M$14.6M$8.9M$3.6M$3.4M
Short-term debt $17.3M$9.2M$850.0K$850.0K$850.0K$13.2M$9.9M$3.3M$3.4M$0
Total current liabilities $278.1M$194.5M$145.5M$99.4M$87.5M$78.6M$61.7M$165.5M$39.2M$31.9M
Long-term debt $291.8M$309.1M$284.8M$285.7M$286.5M$172.4M$175.8M$67.3M$69.9M$0
Total liabilities $899.7M$855.9M$446.8M$421.5M$412.9M$265.5M$244.0M$233.3M$237.4M$153.2M
Retained earnings -$23.1M-$100.3M-$80.1M-$97.3M-$47.8M-$5.0M$17.6M$11.5M-$4.0M-$2.9M
Total equity $540.7M$403.7M$432.7M$313.7M$333.9M$195.7M$212.8M$197.3M$174.8M$169.6M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow $185.2M$64.0M$119.0M-$31.2M$3.3M$15.3M$45.6M$67.1M$39.4M$27.5M
Depreciation and amortisation $8.9M$7.4M$7.5M$7.4M$5.5M$4.8M$44.6M$33.7M$27.9M$22.3M
Stock-based compensation $37.9M$29.3M$20.7M$14.6M$10.5M$12.9M$9.2M$6.8M$6.1M$6.1M
Capital expenditure $13.8M$16.2M$8.9M$8.9M$2.6M$6.1M$6.6M$5.7M$10.4M$4.6M
Investing cash flow -$34.3M-$404.7M-$18.5M-$15.7M-$105.5M-$68.3M-$27.5M-$27.4M-$108.0M-$149.1M
Financing cash flow -$9.9M$264.9M$67.4M-$5.1M$194.6M-$1.4M$1.2M-$27.8M$72.4M-$729.0K
Dividends paid $1.2M$1.6M$1.6M$1.6M$190.0K$0$0———
Buybacks $12.2M$11.0M$5.0M$2.0M$890.0K$1.5M$1.0M$659.0K$259.0K$2.5M

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001023024-26-000039.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -250M 0 250M 500M 750M 1B Revenue, FY2016: 128.6M Gross profit, FY2016: 79.8M Net income, FY2016: 3.9M Revenue, FY2017: 176.8M Gross profit, FY2017: 97.8M Net income, FY2017: -1.1M Revenue, FY2018: 201.6M Gross profit, FY2018: 128.6M Net income, FY2018: 15.5M Revenue, FY2019: 206.5M Gross profit, FY2019: 143.4M Net income, FY2019: 6.1M Revenue, FY2020: 208.5M Gross profit, FY2020: 121.3M Net income, FY2020: -22.5M Revenue, FY2021: 216.1M Net income, FY2021: -43M Revenue, FY2022: 316.4M Net income, FY2022: -48M Revenue, FY2023: 486.8M Net income, FY2023: 19M Revenue, FY2024: 614.4M Net income, FY2024: -19M Revenue, FY2025: 883.4M Net income, FY2025: 78M FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue $128.6M $176.8M $201.6M $206.5M $208.5M $216.1M $316.4M $486.8M $614.4M $883.4M
Gross profit $79.8M $97.8M $128.6M $143.4M $121.3M — — — — —
Net income $3.9M -$1.1M $15.5M $6.1M -$22.5M -$43.0M -$48.0M $19.0M -$19.0M $78.0M

Recent filings and events

  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
  • Officer or director change Item 5.02
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Regulation FD disclosure Item 7.01
  • Results announced Item 2.02
  • Auditor changed The company changed auditors. Sometimes routine; historically one of the more reliable warnings that something is wrong. Item 4.01
  • Regulation FD disclosure Item 7.01
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
  • Results announced Item 2.02
  • Results announced Item 2.02

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 2834

TickerCompanyMarket capP/ERevenue growth
LLY ELI LILLY & Co $1.20T 55.5x 44.7%
JNJ JOHNSON & JOHNSON $635.76B 23.9x 6.0%
ABBV AbbVie Inc. $504.76B 121.0x 8.6%
MRK Merck & Co., Inc. $358.41B 20.0x 1.3%
ABT ABBOTT LABORATORIES $180.63B 27.9x 5.7%
PFE PFIZER INC $171.16B 22.1x -1.6%
VRTX VERTEX PHARMACEUTICALS INC / MA $132.80B 34.2x 8.9%
BMY BRISTOL MYERS SQUIBB CO $125.59B 17.8x -0.2%